Arcadia Biosciences, Inc. (RKDA) - Form 8-K Summary
Business Context and Reporting Period
Arcadia Biosciences, Inc., a Delaware corporation headquartered in Dallas, Texas, filed this Current Report on Form 8-K on May 14, 2026. The filing announces the Company's financial results and business highlights for the first quarter of 2026.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release (Exhibit 99.1) and financial information tables (Exhibit 99.2) referenced in the report but not included in the provided text.
Material Changes
The filing does not explicitly detail material changes versus the prior comparable period within the main text. Investors must refer to the attached exhibits for comparative financial data.
Guidance, Outlook, and Risks
Management commentary, forward-looking guidance, specific risks, contingencies, and unusual items are not detailed in the Form 8-K text itself. This information is incorporated by reference from the attached press release and financial tables.
Investor Verification Checklist
- Review Exhibit 99.1 for the full press release containing Q1 2026 financial results and business highlights.
- Examine Exhibit 99.2 for detailed financial information tables to verify revenue, net loss, and cash position.
- Confirm the trading status of Common Stock (Symbol: RKDA) on The Nasdaq Stock Market LLC.
- Verify the date of the report (May 14, 2026) against the Company's fiscal calendar.